Beijing, Feb 3 (SocialNews.XYZ) China's CanSino Biologics Inc. has got green light to continue phase-3 trials of its Covid-19 vaccine with the support of findings of an independent data monitoring committee, said media reports.
The independent committee "found the drugmaker's Covid-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," the report said.
No adverse events related to the vaccine had occurred, according to the Xinhua news agency.
The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc. and the Academy of Military Sciences in China.
CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China's Ministry of Science and Technology, said in September last year.
Source: IANS
Gopi Adusumilli is a Programmer. He is the editor of SocialNews.XYZ and President of AGK Fire Inc.
He enjoys designing websites, developing mobile applications and publishing news articles on current events from various authenticated news sources.
When it comes to writing he likes to write about current world politics and Indian Movies. His future plans include developing SocialNews.XYZ into a News website that has no bias or judgment towards any.
He can be reached at gopi@socialnews.xyz
This website uses cookies.
